Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

On March 25, Lilly and Boehringer Ingelheim (BI) announced that they submitted an application to the FDA for empagliflozin, an SGLT-2 inhibitor, for type 2 diabetes...
Cellnovo recently launched its mobile-enabled insulin pump system in the UK, after receiving very positive feedback from a usability study that began in the UK in...
Last month, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) released its safety review of incretin-based therapies for diabetes. It...
On January 8, the FDA approved Farxiga (dapaglifozin) for the treatment of type 2 diabetes. The drug is called Forxiga in Europe, where it has been approved since...
On April 16, Vivus announced that the FDA approved a change to the distribution of Qsymia . Qsymia is a weight loss and weight management drug that is designed to be...
Do you ever wonder why there aren’t cheaper “generic” insulin products available? This may soon change as the patents for branded insulin begin to expire. In fact, the...
Last month, in early September, results from the DPP-4 inhibitor cardiovascular outcomes trials SAVOR-TIMI 53 (for Bristol Myers Squibb and AstraZeneca’s Onglyza) and...
On November 22, J&J/Janssen Cilags’ SGLT-2 inhibitor Invokana (canagliflozin) was approved in Europe. This makes Invokana the second SGLT-2 inhibitor approved in...
What it felt like to forget about diabetes for a week.
On February 11, the FDA released a Drug Safety Communication requesting data from the widely publicized cardiovascular outcomes trial for Onglyza (saxagliptin). The...
On September 12, Sanofi announced that it withdrew the FDA application for its once-daily GLP-1 agonist lixisenatide (named Lyxumia in Europe) for type 2 diabetes. It is...
On November 25, the FDA announced the removal of the major restrictions on the prescription and use of GlaxoSmithKline’s Avandia (rosiglitazone) for type 2 diabetes...
The consensus from most speakers at the workshop was that, while this possible link does require further investigation, the available evidence does not suggest any need...
On Tuesday October 15, JDRF and PureTech announced the launch of T1D Innovations, an exciting new fund that aims to supply crucial funding for the development of type 1...
On December 27, Takeda announced that it would stop development of TAK-875 (fasiglifam) due to liver safety concerns – this was one of the most unfortunate announcements...
On June 5 and 6, an FDA advisory panel voted in favor of modifying the current Risk Evaluation and Modification Strategy (REMS), for GlaxoSmithKline’s (GSK) Avandia (...
On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...
A major need for the 79 million Americans with prediabetes…
On December 11, Orexigen announced the resubmission of its weight management drug Contrave (naltrexone/bupropion) to the FDA. The company has previously stated that it...

Pages